AUS
NZ
UK
CA
USA
IND
The Race Oncology Ltd (ASX: RAC) share price has garnered significant investor interest on Tuesday, surging by 16% in morning trading to reach $1.05 per share. This impressive uptick is a direct response to a positive announcement from the ASX healthcare stock, a company focused on oncology within the biotechnology sector.
Positive Interim Clinical Results
Investors have flocked to Race Oncology's shares following the release of interim clinical results from an ongoing investigator-initiated Phase 2 trial. This trial is evaluating bisantrene in combination with fludarabine and clofarabine (Bis/Clo/Flu) for patients with relapsed or refractory Acute Myeloid Leukemia (R/R AML).
The announcement reveals that out of the 15 patients evaluated, 6 patients, or 40%, responded favorably to Bis/Clo/Flu treatment. This response included five complete responses and one partial response. Significantly, three of the clinical responders had active extramedullary disease (EMD).
Promisingly, the ASX All Ords biotech share disclosed that five of the six patients who responded to treatment were successfully bridged to a stem cell transplant (SCT) within one to three months of their treatment.
Of the five patients who underwent SCT, three unfortunately passed away due to various reasons, including graft-versus-host disease, relapse within four months of the transplant, and infection after two years. However, the two remaining patients remain disease-free and in complete remission.
Positive Insights from Clinical Director
The Director of Haematology at the Calvary Mater Newcastle and John Hunter Hospitals, Professor Dr. Anoop Enjeti, offered encouraging insights into the clinical trial's results. He emphasized that the trial combining bisantrene with intensive chemotherapy produced highly promising results in younger AML patients who had advanced relapsed, refractory, and resistant acute myeloid leukemia. Many of these patients achieved either complete or partial remission, allowing a significant portion of them to proceed to a bone marrow transplant.
Professor Dr. Anoop Enjeti also stressed that these impressive results provide proof of concept, supporting further trials of bisantrene in combination with other AML treatments. The ultimate aim is to improve outcomes for individuals battling this form of leukemia.
Conclusion
The Race Oncology Ltd (ASX:RAC) share price has witnessed a substantial increase in value due to the positive interim results from its Phase 2 trial. The fact that 40% of patients demonstrated a positive response to the Bis/Clo/Flu treatment, and that a significant portion of them could undergo stem cell transplants, underscores the potential of this therapy. As the clinical director noted, these results are a significant step toward enhancing the treatment of AML, and further trials are warranted to explore the full potential of bisantrene.
